HS
Harsimran Singh Kalra
About Harsimran Singh Kalra
Data last updated:
Harsimran Singh Kalra is a Director at Janus Biotech India Private Limited (since 2019), Additional Director at Systole Remedies Private Limited (since 2021) and Director at Nyx Pharmaceuticals Private Limited (since 2019), and holds 2 more current directorships. The companies operate in Pharma. The 4 current companies with reported revenue have a combined latest revenue of ₹146 Cr; the largest is Janus Biotech India Private Limited at ₹76.55 Cr (FY 2025).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Janus Biotech India Private Limited U51909CH2019PTC042503 | Director | 07 May 2019 | 2019 | ₹76.55 Cr (FY 2025) | Active |
 Systole Remedies Private Limited U24230DL2005PTC191854 | Additional Director | 17 Jul 2021 | 2005 | ₹59.68 Cr (FY 2025) | Active |
 Nyx Pharmaceuticals Private Limited U51909CH2019PTC042632 | Director | 22 Jul 2019 | 2019 | ₹6.02 Cr (FY 2024) | Active |
 Burgeon Health Series Private Limited U51909CH2021PTC044123 | Director | 31 Dec 2021 | 2021 | ₹3.82 Cr (FY 2025) | Active |
| Flanca Life Sciences Private Limited U51909CH2022PTC044768 | Director | 30 Dec 2022 | 2022 | Active |
Board colleagues of Harsimran Singh Kalra
| Name | DIN | Company | Designation |
|---|---|---|---|
| Jitender Mohan Kalra | 08544394 | Janus Biotech India Private Limited , Systole Remedies Private Limited and 3 more | Director |
| Ravneet Singh | 08445822 | Janus Biotech India Private Limited , Systole Remedies Private Limited and 3 more | Director |
| Ashok Thakur | 11324034 | Systole Remedies Private Limited | Director |
| Mandeep Singh Kalra | 09240146 | Systole Remedies Private Limited , Flanca Life Sciences Private Limited | Additional Director |
| Pavneet Singh Kalra | 09239772 | Systole Remedies Private Limited , Flanca Life Sciences Private Limited | Additional Director |
| Pawan Kumar | 03336280 | Systole Remedies Private Limited | Person Incharge |
| Ashok Kumar | 08516934 | Nyx Pharmaceuticals Private Limited | Director |
| Gaurav Gabbi | 08516935 | Nyx Pharmaceuticals Private Limited | Director |
| Amandeep Singh Anand | 09453668 | Burgeon Health Series Private Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Harsimran Singh Kalra
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Harsimran Singh Kalra
Harsimran Singh Kalra currently holds 5 directorships: Janus Biotech India Private Limited (Director, since 07 May 2019, revenue ₹76.55 Cr (FY 2025)); Systole Remedies Private Limited (Additional Director, since 17 Jul 2021, revenue ₹59.68 Cr (FY 2025)); Nyx Pharmaceuticals Private Limited (Director, since 22 Jul 2019, revenue ₹6.02 Cr (FY 2024)); Burgeon Health Series Private Limited (Director, since 31 Dec 2021, revenue ₹3.82 Cr (FY 2025)); Flanca Life Sciences Private Limited (Director, since 30 Dec 2022).
Harsimran Singh Kalra was first appointed on 07 May 2019 as Director at Janus Biotech India Private Limited. The most recent appointment on record is 30 Dec 2022 at Flanca Life Sciences Private Limited.
The 4 current companies of Harsimran Singh Kalra that report revenue have a combined latest revenue of ₹146 Cr: Janus Biotech India Private Limited ₹76.55 Cr (FY 2025); Systole Remedies Private Limited ₹59.68 Cr (FY 2025); Nyx Pharmaceuticals Private Limited ₹6.02 Cr (FY 2024); Burgeon Health Series Private Limited ₹3.82 Cr (FY 2025).
The current boards of Harsimran Singh Kalra's companies include Jitender Mohan Kalra (Janus Biotech India Private Limited), Ravneet Singh (Janus Biotech India Private Limited), Ashok Thakur (Systole Remedies Private Limited), Mandeep Singh Kalra (Systole Remedies Private Limited), Pavneet Singh Kalra (Systole Remedies Private Limited), Pawan Kumar (Systole Remedies Private Limited), among others.